{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:32:48Z","timestamp":1761514368586,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.cllc.2019.03.003","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T10:38:33Z","timestamp":1553596713000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"20","author":[{"given":"Vivek","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney E.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Miccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin H.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene G.","family":"Finley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses S.","family":"Raj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surbhi","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranshu","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"National Comprehensive Cancer Network","key":"10.1016\/j.cllc.2019.03.003_bib1"},{"key":"10.1016\/j.cllc.2019.03.003_bib2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1080\/03007995.2016.1226165","article-title":"Symptom burden in mesothelioma patients admitted to home palliative care","volume":"32","author":"Mercadante","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cllc.2019.03.003_bib3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.21037\/tlcr.2018.04.10","article-title":"Current chemotherapy strategies in malignant pleural mesothelioma","volume":"7","author":"de Gooijer","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2019.03.003_bib5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/bjc.2015.77","article-title":"The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial","volume":"112","author":"Arnold","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2005.03.3027","volume":"24","author":"Bottomley","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib7","first-page":"2493","article-title":"Randomized trials of systemic medically-treated malignant mesothelioma: a systematic review","volume":"35","author":"Blomberg","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2019.03.003_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.semtcvs.2009.06.006","article-title":"Palliative care for the patient with mesothelioma","volume":"21","author":"Abrahm","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2019.03.003_bib9","first-page":"4025","article-title":"Role of conservative (palliative) care-only in the management of advanced malignant pleural mesothelioma","volume":"32","author":"Levy","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2019.03.003_bib10","first-page":"1879","article-title":"Use of cancer therapy at the end of life in patients with malignant pleural mesothelioma","volume":"21","author":"Kao","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.lungcan.2006.11.005","article-title":"A\u00a0retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005: a single institution experience","volume":"55","author":"Metintas","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib12","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.7314\/APJCP.2013.14.6.3887","article-title":"Second-line chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study","volume":"14","author":"Mutlu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.cllc.2019.03.003_bib13","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2019.03.003_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib15","first-page":"1","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.cllc.2019.03.003_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.cllc.2019.03.003_bib17","first-page":"319","article-title":"Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma","volume":"14","author":"Maniwa","year":"2008","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2019.03.003_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1745-6215-15-367","article-title":"A\u00a0multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial","volume":"15","author":"Gunatilake","year":"2014","journal-title":"Trials"},{"key":"10.1016\/j.cllc.2019.03.003_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2016.07.012","article-title":"Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: report of two cases","volume":"102","author":"Metaxas","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cllc.2019.03.003_bib24","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41571-018-0086-z","article-title":"Economic sustainability of immune-checkpoint inhibitors: the looming threat","volume":"15","author":"Verma","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A\u00a0systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib27","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2017.08.012","article-title":"National Cancer Database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma","volume":"12","author":"Verma","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib28","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2018.08.007","article-title":"Survival by histologic subtype of malignant pleural mesothelioma and the impact of surgical resection on overall survival","volume":"19","author":"Verma","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.lungcan.2018.03.019","article-title":"Facility volume and postoperative outcomes for malignant pleural mesothelioma: a National Cancer Data Base analysis","volume":"120","author":"Verma","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib30","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1245\/s10434-018-6499-1","article-title":"Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival","volume":"25","author":"Verma","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cllc.2019.03.003_bib31","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/j.cllc.2018.04.019","article-title":"Utilization of intensity-modulated radiation therapy for malignant pleural mesothelioma in the United States","volume":"19","author":"Shaaban","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.03.003_bib32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of malignant pleural mesothelioma with chemotherapy preceding versus following surgical resection","volume":"157","author":"Verma","year":"2019","journal-title":"J\u00a0Thorac Cardiovasc Surg"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419300762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:09:31Z","timestamp":1761505771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419300762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1525730419300762"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.03.003","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy Versus Supportive Care for Unresected Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}